Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

PerkinElmer Acquires Analytica

By Drug Discovery Trends Editor | June 22, 2009

PerkinElmer, Inc. has acquired Analytica of Branford, Inc., a recognized pioneer and leader in mass spectrometry (MS) and ion source technology. The acquisition is an integral part of PerkinElmer’s strategic commitment to continue to grow its human and environmental health portfolio. Terms of the acquisition were not disclosed.

With the completion of this acquisition, PerkinElmer will gain significant insight and intellectual property in the field of MS and ion source technology. “Mass spectrometry has proven to be an essential tool in many fields and will continue to be of critical importance. Bringing Analytica’s technology and team of highly innovative experts in-house will dramatically increase our capabilities in this area,” said Richard Begley, Ph.D., president, Analytical Sciences, PerkinElmer.

“The acquisition of Analytica will allow us to offer our customers access to critical technologies such as time-of-flight and quadrupole mass spectrometers and new ion sources that provide more complete information as well as better throughput.” Analytica’s advanced technology complements PerkinElmer’s human and environmental health portfolio. For human health applications, mass spectrometry provides an extremely detailed profile of medically relevant materials in drug discovery and molecular diagnostics. This technology is also the cornerstone of environmental detection and analysis and industrial monitoring. Areas of applications include environmental analysis, pharmaceutical and nutraceutical materials analysis, forensics and food safety.

“This is a wonderful opportunity to apply our outstanding applications and solutions to PerkinElmer’s new and broader end markets,” said Craig Whitehouse, founder and former president of Analytica. “We look forward to combining our resources to develop and provide applications that are critical to people and the environment.” PerkinElmer will integrate Analytica’s current manufacturing operations into its Shelton, CT facility, while utilizing Analytica’s existing Branford facility for R&D projects. Craig Whitehouse will become an employee of PerkinElmer and oversee PerkinElmer’s MS R&D operations.

Date: May 5, 2009
Source: PerkinElmer 


Filed Under: Drug Discovery

 

Related Articles Read More >

TransCelerate CEO Janice Chang wants trials to become part of routine care
STEERLife’s FragMelt platform manufactures drugs with heat sensitive active ingredient 
S&P report highlights Big Pharma’s concentration risk amid pre-JPM deal flurry
Eli Lilly in the Drug Discovery & Development Pharma 50
Lilly Phase 3b trial shows roughly 40-fold higher combined arthritis and weight-loss response
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2026 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE